NCT02973763 is a Phase 1 clinical trial of Alflutinib in NSCLC, sponsored by Allist Pharmaceuticals, Inc..

Who is sponsoring NCT02973763?

NCT02973763 is sponsored by Allist Pharmaceuticals, Inc..

What drugs are being tested in NCT02973763?

Interventions in NCT02973763: Alflutinib.

Is NCT02973763 still recruiting?

NCT02973763 is currently terminated. Last updated 3 April 2025.

Last reviewed 2025-04-03 · How we verify

NCT02973763

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Terminated Phase 1 Last updated 3 April 2025

What this trial tests

Phase 1 trial testing Alflutinib in NSCLC in 14 participants. Terminated before completion.

Timeline

30 December 2016

Primary endpoint
4 February 2021

1 August 2023

Quick facts

Lead sponsor	Allist Pharmaceuticals, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	30 December 2016
Primary completion	4 February 2021
Estimated completion	1 August 2023

Drugs / interventions tested

Alflutinib — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →

Sponsor

Allist Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Alflutinib Mesylate Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model. This study aims at local advanced or metastatic non-small cell lung cancer patients with T790M drug-resistant mutation.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L, Li Y, Xiong L, Wang W, et al · · 2021 · cited 1003× · PMID 34054126 · DOI 10.1038/s41392-021-00572-w
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu AB, Munteanu R, Moldovan CS, et al · · 2024 · cited 133× · PMID 39138146 · DOI 10.1038/s41392-024-01899-w
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
Shi Y, Zhang S, Hu X, Feng J, et al · · 2020 · cited 78× · PMID 32007598 · DOI 10.1016/j.jtho.2020.01.010
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
Sa H, Shi Y, Ding C, Ma K. · · 2023 · cited 21× · PMID 37004599 · DOI 10.1007/s00432-023-04726-x
Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review.
Su S, Wu YL. · · 2017 · cited 19× · PMID 28784178 · DOI 10.1186/s13045-017-0514-z
Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model.
Zou HX, Zhang YF, Zhong DF, Jiang Y, et al · · 2022 · cited 8× · PMID 34789919 · DOI 10.1038/s41401-021-00798-y
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity.
Lee CS, Sharma S, Miao E, Mensah C, et al · · 2020 · cited 8× · PMID 33117017 · DOI 10.2147/lctt.s258444
A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects.
Zhu S, Deng J, Tang Q, Heng J, et al · · 2020 · cited 4× · PMID 33680007 · DOI 10.22037/ijpr.2020.113112.14116

Verify or expand the search:

Other trials of Alflutinib

Trials testing the same drug.

NCT03452592 — Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M · Phase 2 · terminated
NCT03127449 — AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations · NA · terminated

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Allist Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT07010419 — A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With St · Phase 3 · recruiting
NCT06416410 — JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06162169 — A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects · Phase 1 · completed
NCT06008288 — A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor · Phase 2 · recruiting
NCT05920941 — Mass Balance Study of [14C]JAB-21822 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02973763 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allist Pharmaceuticals, Inc.
Last refreshed: 3 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02973763.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing